Patient perspectives on non‑traumatic painful upper‑extremity conditions, co-occurring risky substance use, and an integrated web-based mind-body intervention addressing both conditions.
Recent qualitative research examining upper extremity pain and substance use management reveals patients commonly use alcohol, cannabis, and tobacco for symptom relief but lack awareness of pain-substance interactions. The study provides insights for…
Cognitive performance and subjective effects the morning after last use of smoked cannabis by adults who use cannabis frequently: An observational study.
A controlled observational study found no cognitive impairment in regular cannabis users 12-15 hours after smoking, with important implications for understanding cannabis cognitive effects next day. This research provides evidence that cognitive function…
Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.
This cannabis flower anxiety relief study found that flower products provide superior anxiety reduction compared to edibles. Therapeutically motivated users experienced different daily and longitudinal effects. Individual responses vary, highlighting the…
Randomized and Blind Evaluation of the Efficacy of a Full-Spectrum Oral Cannabis Extract
This randomized clinical trial demonstrates that full-spectrum cannabis osteoarthritis pain relief is significant compared to placebo. The study provides controlled evidence supporting cannabinoid analgesic effects in degenerative joint disease. These…
Reducing Severe Breathlessness with Dronabinol in Severe COPD Patients
A new randomized crossover trial will investigate whether dronabinol COPD breathlessness treatment can help patients with severe symptoms. This protocol review examines the study design and clinical context for cannabis medicine in respiratory care. The…
Analgesic Effect of Cannabinoids for Fibromyalgia: A Systematic Review and Meta-Analysis
This meta-analysis highlights cannabinoid analgesia fibromyalgia benefits with statistically significant pain reduction. Fibromyalgia patients often face inadequate relief from conventional therapies. Cannabinoid analgesia fibromyalgia offers a promising…
Cannabis-Based Medicines for Chronic Neuropathic Pain in Adults
The 2025 Cochrane review on cannabis-based medicines neuropathic pain provides the most rigorous analysis of cannabinoid effectiveness for chronic nerve pain. This systematic review update incorporates recent trial data to inform evidence-based clinical…
The efficacy and safety of cannabinoids for mental and substance use disorders: a systematic review and meta-analysis
A landmark cannabinoids mental health disorders systematic review published in The Lancet Psychiatry examines cannabinoids for mental health and substance use disorders. This comprehensive analysis addresses critical evidence gaps. The findings directly…
Why Averages Fail Palliative Cannabis Patients – A New Framework
Randomized controlled trials often fail to capture what palliative care cannabis patients actually experience. A new contextual effectiveness framework argues that averaging subjective outcomes obscures genuine individual benefit. This Evidence Brief…
U.S. Department of Justice Issues Final Order Rescheduling Medical Cannabis
The final order rescheduling medical cannabis to Schedule III marks a pivotal federal policy shift. This change removes longstanding barriers to clinical research. It enables FDA-approved studies and standardized trials to advance cannabis medicine.